GSK-205050

Study Sponsor: GSK

Study Title

Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis

Medicine or Vaccine (generic name)

mepolizumab

Sponsor Identification Number

205050

Trial Registry Identification Number(#'s)

NCT03055195

Medical Condition

Dermatitis, Atopic

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=205050

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT03055195

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

October 2019